







AML NEWLY DIAGNOSED: NON-INTENSIVE

UCI 21-216

Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy FLT3 mutation

Mechanism: FLT3 inhibitor

PI: Jeyakumar Coord: S. Osorio Accrual: 1/5

POLYCYTHEMIA VERA

UCI 21-204

ISIS702843 in patients w/ PD-PC

Mechanism: Antisense oligonucleotide specific for human transmembrane protease serine 6

> PI: Fleischman Coord: K. McAbee Accrual: 1/5





Low Accruing Pending Activation/Suspended

CLL RELAPSED/REFRACTORY: 2L+

UCI 21-209

LOXO-305 + Venetoclax and Rituximab vs. Venetoclax and Rituximab in previously treated CLL/SLL

Mechanism: BTK inhibitor + BCL2 inhibitor + CD20 marker

PI: Coombs Coord: S. Osorio Accrual: 2/3

CLL NEWLY DIAGNOSED: HIGH RISK

SWOG S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs Coord: S. Osorio Accrual: 1/10





CRC: ADJUVANT

GASTRIC/GEJ: NEWLY DIAGNOSED METASTATIC

NRG GI005/COBRA

(SOC vs mFOLFOX6 or CAPOX or surveillance)

PI: Zell Coord: L. Aguilar Accrual: 2/5

ECOG EA2183

Open to Accrual

(SOC + XRT)

PI: Seyedin Coord: J. Koff Accrual: 0/10

<u>UCI 21-193</u>

Low Accruing Pending Activation/Suspended

(FGFR inhibitor + mFOLFOX6 + antiPD-L1 (nivolumab)

PI: Dayyani Coord: M. Nguyen Accrual: 1/12

GASTRIC/GEJ: NEOADJUVANT

UCI 21-191

(SOC therapy with ctDNA testing)

PI: Dayyani Coord: A. Luna Pending activation





<u>UCI 18-136</u>

PI: Parajuli Coord: B. Sanchez/C. Carlton Accrual: 64/100

UCI 17-05 (BRCA1 -/+)

PI: Parajuli Coord: B. Sanchez Accrual: 48/75 Open to Accrual Low Accruing Pending Activation/Suspended

ADJUVANT

<u>ALLIANCE A011801 (HER2+)</u>

Antibody drug conjugate + kinase inhibitor

PI: Parajuli Coord: Stephany Ruiz Accrual: 2/5

UCI 22-141 (TNBC)

PDL-1 inhibitor

PI: Parajuli Coord: Stephany Ruiz Accrual: 0/5



Open to Accrual Low Accruing Pending Activation/Suspended

1L METASTATIC

2L METASTATIC

3L METASTATIC

ETCTN 10546 (TNBC)

Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA) PI: Parajuli; Coord: K. Kaminski/D. Huttar Accrual: 1/5

UCI 19-145 (HR+/HER2-)

CDK 4/6 inhibitor + ER Regulator + Aromatase Inhibitor PI: Mehta; Coord: S. Ruiz Accrual: 9/20

UCI 21-212 (TNBC)

Antibody drug conjugate PI: Parajuli; Coord: St. Ruiz/J. Miranda Accrual: 0/3

ETCTN 10551 (germline BRCA 1/2+)

Hu5F9-G4 (magrolimab) recombinant humanized anti-CD47 mAb IgG4 PI: Parajuli; Coord: A. Chavez Accrual: 0/5

UCI 22-139 (HR+/HER2-)

PI3K/mTOR inhibitor PI: Parajuli; Coord: Alexis Chavez Accrual: 2/5

UCI 22-114 (ER+/HER2-)

Proteasome-mediated degradation PI: Parajuli; Coord: Alexis Chavez Accrual: 3/5



8



HCC: LOCOREGIONAL

UCI 19-49

Cabo + Ipi/Nivo + TACE

PI: Dayyani Coord: Han Nguyen Accrual: 15/35

HCC: 1-3L

UCI 22-106

STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab

PI: Dayyani Coord: H. Nguyen Accrual: 5/10



Open to Accrual Low Accruing Pending Activation/Suspended

PANCREATIC: BORDERLINE/LOCALLY ADVANCED

ETCTN 10366

M3814 (Peposertib) + radiation therapy

PI: Dayyani Coord: H. Nguyen Accrual: 4/8





MELANOMA: NON-TREATMENT


UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

> PI: Yamamoto Coord: A. Reipolska Accrual: 68/90







SARCOMA: RECURRENT

ETCTN 10556

Ipilimumab and Nivolumab +/- Cabozantinib

PI: Chow Coord: B. Huynh Accrual: 1/5





KRAS

UCI 22-75

KRAS targeted Vaccine

PI: Valerin Coord: M. Duron Accrual: 1/7





Open to Accrual Low Accruing Pending Activation/Suspended

CLDN18.2

UCI 21-10

Bispecific antibody (anti-CLDN18.2 + anti-4-1BB)

PI: Dayyani Coord: K. Ghio Accrual: 10/17

NON-TREATMENT

UCI 20-101

(Biospecimen Collection for patients planned to start treatment)

PI: Senthil Coord: N. Arechiga Accrual: 53/80

SWOG S1823

Low risk group (Stage I/IA) Moderate risk group (Stage IIA/IB) High risk group (nonseminoma Stage IS only)

> PI: Rezazadeh Coord: K. Cung Accrual 3/8

